Edoxaban intermediate and its manufacturing method
The enzyme-catalyzed method for producing edoxaban intermediates addresses the challenges of racemic formation and harsh conditions in chemical synthesis, achieving high yields and chiral purity suitable for industrial production.
Patent Information
- Application Number
- JP2024536409
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-31
- Filing Date
- 2022-11-21
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2042-11-21
AI Technical Summary
The synthesis of chiral substrates for edoxaban intermediates is challenging due to issues such as racemic formation, low yields, and harsh reaction conditions in existing chemical methods.
An enzyme-catalyzed method is employed to produce edoxaban intermediates using transaminase enzymes and mild reaction conditions, involving steps of oxidation and enzyme-catalyzed reactions to achieve high chiral purity and yield.
The enzyme-catalyzed method achieves high yields and chiral purity with environmentally friendly solvents and simple process operations, suitable for industrial production.
Smart Images

Figure 2024543705000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of biocatalysis, specifically to a key intermediate of edoxaban and an enzyme-catalyzed preparation method thereof. [Background technology]
[0002] Edoxaban p-toluenesulfonate monohydrate is a small molecule drug developed by Daiichi Sankyo Co., Ltd. and is a blood coagulation factor Xa inhibitor. Currently, the highest research and development stage of the drug is to obtain marketing approval, and it treats pulmonary embolism, venous thromboembolism, stroke, venous thrombosis and embolism. On April 22, 2011, Edoxaban toluenesulfonate was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) and is marketed by Daiichi Sankyo Co., Ltd. On January 8, 2015, Edoxaban toluenesulfonate was approved by the US Food and Drug Administration (FDA) and is marketed by Daiichi Sankyo Inc. under the trade name Savaysa®. (NDA206316) On June 19, 2015, Edoxaban toluenesulfonate was approved by the European Medicines Agency (EMA) and is marketed by Daiichi Sankyo Europe Gmbh under the trade name Lixiana®. (EMEA / H / C / 002629) On December 25, 2018, edoxaban toluenesulfonate was approved by the China National Medical Products Administration (NMPA) and is marketed by Daiichi Sankyo Europe Gmbh under the trade name Lixianan®.
[0003] Edoxaban has three chiral centers and has a total of eight isomers, but only one configuration has good activity. The structure of edoxaban is as follows: [ka]
[0004] The synthetic route developed by Nippon Daiichi Sankyo Co., Ltd. and disclosed in WO2008156159A1 is as follows: Racemic S-1 is decomposed in the presence of chiral amine S-2, and then under the action of an electrophilic bromination reagent, it is subjected to intramolecular nucleophilic attack to obtain bridged ring compound S-4. S-4 is aminolyzed and ring-opened via propylene oxide intermediate S-6 under the action of NH4OH to obtain amino alcohol compound S-7. S-7 is then protected by Boc for amino group protection, Ms for alcohol hydroxy group protection, and NaN3 attack to introduce N3 group to obtain compound S-10. Then, the amino group is obtained by hydrogenation reduction, and then condensed with S-13 to obtain compound S-14. Compound S-14 is subjected to removal of the Boc protecting group under acidic conditions, and then condensed with carboxylic acid S-16 to obtain the final compound S-17, which can be converted to a TsOH salt to obtain edoxaban. The synthetic route of the process is as follows: [ka]
[0005] The difficulty in synthesizing this compound is the preparation of chiral substrates such as compound S-10.
[0006] In the synthetic route disclosed by Japan Daiichi Sankyo Co., Ltd. in patent CN101263110, the substitution of methanesulfonate with sodium azide produces more than 10% racemate. The synthetic route of this process is as follows: [ka]
[0007] Daiichi Sankyo Co., Ltd. has published the following in CN105008325A, DOI:10.1021 / acs.oprd.8b00413. The process route has been optimized, and the Burgess reagent has been used to avoid the racemic problem in the first generation route, improving the yield by 20%, but the reagent generates a lot of heat during use, and the amplification effect during the amplification process is significant. The synthetic route of the process is as follows: [ka]
[0008] CN106866452 discloses a method for constructing an amino chiral center by chemical methods, which is difficult to reproduce. The synthetic route of this process is as follows: [ka] Summary of the Invention
[0009] The technical problem to be solved by the present invention is to provide a method for producing a key intermediate of edoxaban by an enzyme catalysis.
[0010] In order to solve the above problems, the present invention uses the following technical means.
[0011] Edoxaban intermediates have the general structural formula represented by Formula I or Formula II. [ka] [ka] In the formula, R1 is OH, an alkoxy group, or an N,N-dialkyl group, and R2 is hydrogen, an alkoxycarbonyl group, or another amino protecting group.
[0012] Preferably, in the general structural formula, R1 is N,N-dimethyl or ethoxy, and R2 is hydrogen, tert-butoxycarbonyl, benzyloxycarbonyl, ethoxycarbonyl, benzyl or benzoyl.
[0013] The present invention further provides a method for producing the above-mentioned edoxaban intermediate, comprising the following steps 1) and 2):
[0014] In step 1), a compound of formula II is obtained by oxidizing a compound of formula III. [ka]
[0015] The process route of step 1) is as follows: [ka]
[0016] In step 2), the compound of formula II, transaminase, transaminase coenzyme and phosphate buffer solution are mixed together to carry out an enzyme-catalyzed reaction or further an amine derivatization reaction, and then the compound of formula I is obtained.
[0017] The process route of step 2) is as follows: [ka]
[0018] Preferably, the oxidizing agent in step 1) is John's reagent, PCC reagent or TEMPO reagent, preferably TEMPO reagent.
[0019] Preferably, the transaminase in step 2) is selected from the transaminase library of Suntory Biotechnology (Shanghai) Co., Ltd.
[0020] Preferably, in the system of step 2), the substrate concentration is 10 to 100 g / L, the transaminase is involved in the reaction in the form of one or a combination of wet cells and liquid enzymes, and when the transaminase is added in the form of a liquid enzyme, the mass ratio of the liquid enzyme is 1 to 20%, the reaction temperature is 0 to 30° C., the reaction pH value is 6.5 to 7.0, and the reaction time is 12 to 30 hours.
[0021] Preferably, in step 2), the concentration of the compound of formula II is 10 to 100 g / L, the concentration of the transaminase is 5 to 20 g / L, the concentration of the transaminase coenzyme is 1 to 10 mg / L, and the concentration of the phosphate buffer is 10 to 100 mM.
[0022] Preferably, after obtaining the amine product by the amine derivatization reaction in the above step 2), the characteristic reaction of the amine functional group protecting group is to directly add a protecting group reagent to the reaction solution of the enzyme-catalyzed reaction to carry out the reaction.
[0023] Preferably, the method further comprises a post-treatment step of adding a filter aid to the reaction solution after the completion of the reaction in step 2), and then filtering, extracting, concentrating and crystallizing the solution to obtain the compound of formula I.
[0024] More preferably, the filter aid is diatomaceous earth.
[0025] The process route of the present invention is as follows: [ka]
[0026] Furthermore, the compound of formula III can be prepared by the following method. [ka]
[0027] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0028] The enzyme-catalyzed preparation method of the compound of formula I provided by the present invention can achieve high yield and chiral purity, requires a small amount of environmentally friendly organic solvent, has mild reaction conditions, and is simple in process operation, making it suitable for industrial production.
[0029] In order to further confirm the key step described in the present invention, i.e. the chiral configuration of the amino chiral center constructed by transaminase, the present invention obtains the compound of formula V after derivatizing the obtained compound of formula I-2 as follows, and also obtains the single crystal X-ray diffraction pattern of the compound of formula V through experiment, which further confirms that the absolute configuration of the key intermediate obtained in the present invention is correct. [ka] [Brief description of the drawings]
[0030] [Figure 1] FIG. 1 is an HPLC spectrum of the compound of formula V, ((1R,2S,5S)-2-(((benzyloxy)carbonyl)amino)-5-(dimethylcarbamoyl)cyclohexyl)-14-azocarboxylic acid tert-butyl ester. [Diagram 2] FIG. 1 is an HPLC spectrum of the compound of formula V ((1R,2S,5S)-2-(((benzyloxy)carbonyl)amino)-5-(dimethylcarbamoyl)cyclohexyl)-14-azocarboxylic acid tert-butyl ester and its chiral isomers. [Diagram 3] FIG. 1 is a single crystal X-ray diffraction spectrum of the compound of formula V, ((1R,2S,5S)-2-(((benzyloxy)carbonyl)amino)-5-(dimethylcarbamoyl)cyclohexyl)-14-azocarboxylic acid tert-butyl ester. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0031] In order that the present invention may be more clearly understood, a preferred embodiment will now be described in detail with reference to the drawings.
[0032] Example 1 Preparation of (1S,4S,5S)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (IV) [ka] (S)-3-cyclohexene carboxylic acid (126.2 g, 1.0 mol), 200 mL of water and potassium hydroxide (41 g, 1.05 mol) were added to the reaction flask in sequence, the reaction system was stirred to cool to about -10 ° C, NBS (196 g, 1.1 mol) was gradually added, and after the addition was completed, the temperature of the reaction system was kept at about -5 to 5 ° C and stirred for 1 hour to react, and monitored by TLC. After the reaction was completed, sodium sulfite (25.2 g, 0.2 mol) was added, and the reaction was stirred for 0.5 hours, and then filtered to obtain 198.8 g of compound III, with a yield of 97%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows.
[0033] 1 H NMR(400 MHz,Chloroform-d)δ4.79(d,J=5.1 Hz,1H),4.39(d,J=4.7 Hz,1H),2.65(d,J=12.3 Hz,2H),2.46-2.35(m,1H),2.35-2.27(m,1H),2.13(dd,J=16.4,5.4 Hz,1H),1.93(dt,J=12.9,5.5,2.2 Hz,1H),1.84(dt,J=12.1,11.0,4.9,3.1 Hz,1H).
[0034] A series of methods for preparing compound III by a one-pot method are typified where R is OCH2CH3 and N(CH3)2.
[0035] Example 2 Preparation of (1S,3R,4R)-3-azido-4-hydroxycyclohexane-1-carboxylic acid ethyl ester (III-1) [ka] Compound IV (20.5 g, 0.1 mol) and 20 mL of ethanol were added to a 100 mL three-neck flask, cooled to 0-5 ° C., sodium ethoxide (10.2 g, 0.15 mol) was gradually added to the above reaction system, and the reaction system was stirred for 1-2 hours while keeping the temperature at 0-5 ° C., and 30 mL of water and sodium azide (9.7 g, 0.15 mol) were added to the above reaction system, and the reaction system was stirred for 3 hours while raising the temperature to 15-20 ° C., and 50 mL of dichloromethane was added to separate the mixture. The dichloromethane layer was concentrated under reduced pressure to remove dichloromethane, and compound III-1 (18.7 g) was obtained, with a yield of 88.4%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows.
[0036] 1 H NMR(400 MHz,CDCl3)δ4.16(dd,J=7.2,1.2 Hz,2H),3.52(dt,J=24.7,8.5,4.0 Hz,2H),2.72(d,J=4.8 Hz,1H),2.59-2.48(m,1H),2.36(dt,J=14.0,4.4 Hz,1H),2.14-2.05(m,1H),1.95-1.85(m,1H),1.63-1.46(m,3H),1.26(dt,J=8.9,5.1,1.4 Hz,3H).
[0037] Example 3 Preparation of (1S,3R,4R)-3-azido-4-hydroxy-N,N-dimethylcyclohexane-1-carboxamide (III-2) [ka] Compound IV (20.5 g, 0.1 mol) and 20 mL of acetonitrile were added to a 250 mL three-neck flask, cooled to 0-5 ° C., 40% dimethylamine aqueous solution (16.8 g, 0.15 mol) was added, and the mixture was stirred and reacted for 10-11 hours while keeping the temperature at 0-5 ° C. Dimethylamine and acetonitrile were distilled off under reduced pressure, 30 mL of water and sodium hydroxide (6 g, 0.15 mol) were added, and the mixture was stirred and reacted at 0-10 ° C. for 5-6 hours, and sodium azide (9.7 g, 0.15 mol) was weighed and added to the system, and the mixture was heated to 15-20 ° C. and stirred and reacted for 3-4 hours, and 50 mL of dichloromethane was added and separated, and the dichloromethane layer was concentrated under reduced pressure to remove dichloromethane, to obtain compound III-1 (19.1 g), with a yield of 90.1%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows.
[0038] 1 HNMR(400 MHz,CDCl3)δ3.98(dd,J=10.0,6.0 Hz,1H),3.64(s,1H),3.43(s,1H),3.03(s,3H),2.91(s,3H),2.88(d,J=3.9 Hz,1H),2.23-2.09(m,1H),1.95-1.77(m,2H),1.76-1.65(m,1H),1.54(dt,J=16.4,5.8 Hz,2H). 13 C NMR (101 MHz, CDCl3) δ174.93,69.31,62.25,37.34,35.70,34.58,29.01,28.11,23.48.
[0039] Example 4 Preparation of (1S,3R)-4-azido-4-oxocyclohexane-1-carboxylic acid ethyl ester (II-1) [ka] Compound III-1 (2.1g, 0.01mol), sodium bicarbonate (1.9g, 0.02mol), sodium bromide (0.1g, 0.001mol) and TEMPO (0.08g, 4%, w / w) were added to a 100mL three-neck flask, 15mL of dichloromethane was added and stirred to dissolve, the temperature was lowered to -5 to 0 ° C, and an aqueous sodium hypochlorite solution (15.8g, 0.015mol) was weighed and gradually dropped into the reaction system, the temperature was kept below 0 ° C, and after the dropwise addition, the mixture was stirred for 0.5 to 1.0 hours, left to stand and separated, and the dichloromethane layer was concentrated under reduced pressure to remove the solvent, obtaining compound II-1 (1.9g), with a yield of 90.5%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows.
[0040] 1 H NMR(400 MHz,CDCl3)δ4.16(dd,J=7.2,1.2 Hz,2H),3.9(d,J=4.8 Hz,1H),2.72(d,J=4.8 Hz,1H),2.36(dd,J=14.0,4.4 Hz,1H),2.14-2.05(m,1H),1.95-1.85(m,1H),1.63-1.46(m,3H),1.26(dd,J=8.9,5.1,1.4 Hz,3H). 13 C NMR (125 MHz, CDCl3) δ209.75,174.15,60.85,59.37,39.24,36.44,34.75,27.08,14.26.
[0041] Example 5 Preparation of (1S,3R)-3-azido-N,N-dimethyl-4-oxocyclohexane-1-carboxamide (II-2) [ka] Compound III-2 (2.1g, 0.01mol), sodium bicarbonate (1.9g, 0.02mol), sodium bromide (0.1g, 0.001mol) and TEMPO (0.08g, 4%, w / w) were added to a 100mL three-neck flask, 15mL of dichloromethane was added and stirred to dissolve, the temperature was lowered to -5 to 0 ° C, and an aqueous solution of sodium hypochlorite (15.8g, 0.015mol) was weighed and gradually dropped into the reaction system, the temperature was kept below 0 ° C, and after the dropwise addition, the mixture was stirred for 0.5 to 1.0 hours, left to stand and separated, and the dichloromethane layer was concentrated under reduced pressure to remove the solvent, obtaining compound II-2 (1.8g), with a yield of 86.5%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows.
[0042] 1 H NMR(400 MHz,CDCl3)δ4.68-4.56(m,1H),3.17(dd,J=11.2,6.7 Hz,1H),3.07(s,3H),2.95(s,3H),2.76- 2.63(m,1H),2.49(dd,J=11.7,4.9 Hz,1H),2.32(dd,J=13.4,5.5 Hz,1H),2.14-2.02(m,1H),2.02-1.91(m,1H),1.91-1.79(m,1H). 13 C NMR(101 MHz, CDCl3) d 205.55,173.40,63.68,37.21,37.06,35.27,34.27,33.94,27.86.
[0043] Example 6 Preparation of (1S,3R,4S)-4-amino-3-azidocyclohexane-1-carboxylic acid ethyl ester (I-1) [ka] Compound II-1 (5 g), PBS buffer (pH 7.0, 1M, 50 mL), water (350 mL), PLP (2.6 mg, 5.3 mg / L), isopropylamine (100 mL, 50 g / L) and ATA101 (5.0 g) were added to a 500 mL reaction flask and reacted for 25-30 hours with mechanical stirring at 25-30 °C. After the reaction was completed, the mixture was filtered through diatomaceous earth and the mother liquor was extracted with dichloromethane to obtain compound I-1 (4.3 g), with a yield of 86.5%.
[0044] Example 7 Preparation of (1S,3R,4S)-4-amino-3-azido-N,N-dimethylcyclohexane-1-carboxamide (I-2) [ka] Compound II-2 (5 g), PBS buffer (pH 7.0, 1M, 50 mL), water (350 mL), PLP (2.6 mg, 5.3 mg / L), isopropylamine (50 mL, 100 g / L) and ATA101 (5.0 g) were added to a 500 mL reaction flask, and the mixture was reacted for 25 to 30 hours at 25 to 30 ° C with mechanical stirring. After the reaction was completed, the mixture was filtered through diatomaceous earth, and the mother liquor was extracted with dichloromethane to obtain compound I-2. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows:
[0045] 1 H NMR(400 MHz,CDCl3)δ3.82(d,J=2.3 Hz,1H),2.99(s,3H),2.85(s,3H),2.79-2.63(m,2H),1.92(dd,J=14.3,2.7 Hz, 1H), 1.87-1.72 (m, 1H), 1.72-1.56 (m, 2H), 1.54-1.18 (m, 4H). 13 C NMR (101 MHz, CDCl3) δ174.62,64.49,52.00,37.08,35.53,33.66,32.15,30.05,27.55.
[0046] Example 8 Preparation of (1S,3R,4S)-3-azido-4-(tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid ethyl ester (I-3) [ka] Compound I-1 (2.1 g, 10 mmol), BocO (2.6 g, 12 mmol), potassium carbonate (2.1 g, 15 mmol) and 50 mL of water were added to a 100 mL three-neck flask at once, and the mixture was heated to 40-50°C and reacted with stirring for 3-4 hours to precipitate a white solid. The solid was filtered by suction under reduced pressure to obtain 2.8 g of compound I-3, with a yield of 90%.
[0047] Example 9 Preparation of ((1S,2R,4S)-2-azido-4-(dimethylcarbamoyl)cyclohexyl)carbamic acid tert-butyl ester (I-4) [ka] Compound I-2 (2.1g, 10mmol), Boc2O (2.6g, 12mmol), potassium carbonate (2.1g, 15mmol) and 50mL of water were added to a 100mL three-neck flask at once, heated to 40-50°C, stirred and reacted for 3-4 hours, precipitated a white solid, and filtered by reduced pressure suction to obtain 2.9g of compound I-4, with a yield of 94%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows:
[0048] 1 H NMR(400 MHz,CDCl3)δ4.87(d,J=7.2 Hz,1H),4.03(s,1H),3.54(s,1H),2.95(s,3H),2.82(s,3H),2.70(t,J=11.1 Hz,1H),1.85(dd,J=31.3,13.5 Hz, 2H), 1.66 (t, J=13.1 Hz, 2H), 1.57 - 1.40 (m, 2H), 1.33 (s, 9H). 13C NMR (101 MHz, CDCl3) δ174.20,154.89,79.42,61.16,50.94,37.00,35.48,33.51,31.83,28.24,27.41,26.40.
[0049] Example 10 Preparation of ((1S,2R,4S)-2-azido-4-(dimethylcarbamoyl)cyclohexyl)carbamic acid methyl ester (I-5) [ka] Compound I-2 (2.0 g) was added with 2-methyltetrahydrofuran (80 mL), sodium bicarbonate (1.6 g, 2.0 eq) was added, and the mixture was stirred at room temperature. Methyl chloroformate (1.2 g, 1.3 eq) was added to the system, and the mixture was stirred for 2-3 hours. The mixture was detected by TLC. After the conversion of the raw material was completed, the insoluble matter was removed by filtration, the filter cake was washed with 2-methyltetrahydrofuran, the filtrate was separated, the organic phase was concentrated, and the product was recrystallized with PE / EA to obtain a white solid I-5, with a yield of 84%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows:
[0050] 1 H NMR(400 MHz,CDCl3)δ4.87(d,J=8.5 Hz,1H),4.13(d,J=4.2 Hz,1H),3.69(s,4H),3.08(s,3H),2.96(s,3H),2.83(d,J=11.7,3.6 Hz, 1H), 2.09-1.92 (m, 2H), 1.84-1.75 (m, 2H), 1.67-1.45 (m, 2H).
[0051] Example 11 Preparation of ((1S,2R,4S)-2-azido-4-(dimethylcarbamoyl)cyclohexyl)carbamic acid benzyl ester (compound I-6) [ka] Compound I-2 (2.0 g) was added with 2-methyltetrahydrofuran (80 mL), sodium bicarbonate (1.6 g, 2.0 eq) was added, and the mixture was stirred at room temperature. Benzyl chloroformate (2.1 g, 1.3 eq) was added to the system, and the mixture was stirred for 2-3 hours. The mixture was detected by TLC. After the conversion of the raw material was completed, the insoluble matter was removed by filtration, the filter cake was washed with 2-methyltetrahydrofuran, the filtrate was separated, the organic phase was concentrated, and the product was recrystallized with PE / EA to obtain a white solid I-6, with a yield of 86%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows:
[0052] 1 H NMR(400 MHz,CDCl3)δ7.41-7.30(m,5H),5.12(s,2H),4.95(d,J=8.5 Hz,1H),4.14(s,1H),3.83-3.69(m,1H),3.08(s,3H),2.96(s,3H),2.90-2.75(m,1H),2.10-1.91(m,2H),1.81(d,J=12.6 Hz, 2H), 1.69 (s, 1H), 1.58-1.46 (m, 1H).
[0053] Example 12 Preparation of ((1R,2S,5S)-2-(((benzyloxy)carbonyl)amino)-5-(dimethylcarbamoyl)cyclohexyl)-14-azocarboxylic acid tert-butyl ester (V) [ka] Compound I-6 (1.05 g) was added with triphenylphosphine (2.4 g, 3.0 eq), tetrahydrofuran (30 mL), and deionized water (7 mL). After the reaction was completed, 1N HCl was added to adjust the pH to 2-3, and the mixture was concentrated to remove tetrahydrofuran. The aqueous phase was extracted with dichloromethane, the aqueous phase was reserved, and sodium hydroxide was added to adjust the pH of the aqueous phase to 8-9. Boc anhydride (1.0 g, 1.5 eq) was added and stirred overnight, and the mixture was filtered and washed with suction to obtain a white solid V, with a yield of 85%. The proton nuclear magnetic resonance spectrum data of the obtained product is as follows:
[0054] 1 H NMR(400 MHz,cdcl3)δ7.38 - 7.26(m,5H),5.22(s,1H),5.09(t,J=10.3 Hz,2H),4.12(s,1H),3.70(s,1H),3.02(s,3H),2.92(s,3H),2.62(s,1H),1.99(d,J=37.6 Hz,2H),1.72(d,J=18.7 Hz,5H),1.43(s,9H)。
Claims
1. An edoxaban intermediate, characterized in that the general structural formula is represented by Formula I or Formula II. 【Chemistry 1】 【Chemistry 2】 (In the formula, R 1 is OH, an alkoxy group or an N,N-dialkyl group, and R 2 is hydrogen, an alkoxycarbonyl group, or an amino protecting group.
2. In the general structural formula, R 1 is an N,N-dimethyl or ethoxy group, R 2 is hydrogen, tert-butoxycarbonyl, benzyloxycarbonyl, ethoxycarbonyl, benzyl or benzoyl; The edoxaban intermediate of claim 1.
3. Step 1) of oxidizing a compound of formula III to obtain a compound of formula II; 【Chemistry 3】 2) mixing the compound of formula II, a transaminase, a transaminase coenzyme and a phosphate buffer solution for enzyme-catalyzed reaction or further amine derivatization reaction, followed by obtaining the compound of formula I; The method for producing the edoxaban intermediate according to claim 1 or 2.
4. The oxidizing agent in step 1) is John's reagent, PCC reagent or TEMPO reagent. The method for producing the edoxaban intermediate according to claim 3 .
5. The transaminase in step 2) is selected from the transaminase library of Suntory Biotechnology (Shanghai) Co., Ltd.; The method according to claim 3 .
6. In the system of step 2), the concentration of the substrate is 10 to 100 g / L, the transaminase is involved in the reaction in the form of one or a combination of wet cells and liquid enzymes, and when the transaminase is added in the form of a liquid enzyme, the mass ratio of the liquid enzyme is 1 to 20%, the reaction temperature is 0 to 30° C., the reaction pH value is 6.5 to 7.0, and the reaction time is 12 to 30 hours. The method according to claim 3 .
7. In the step 2), the concentration of the compound of formula II is 10-100 g / L, the concentration of the transaminase is 5-20 g / L, the concentration of the transaminase coenzyme is 1-10 mg / L, and the concentration of the phosphate buffer is 10-100 mM; The method according to claim 3 .
8. After obtaining the amine product by the amine derivatization reaction in the above step 2), the characteristic reaction of the amine functional group protecting group is to directly add a protecting group reagent to the reaction solution of the enzyme-catalyzed reaction, and react; The method according to claim 3 .
9. The reaction solution after the reaction of step 2) is added with a filter aid, and the reaction solution is filtered, extracted, concentrated, and crystallized to obtain the compound of formula I. The method according to claim 3 .
10. The filter aid is diatomaceous earth. The method according to claim 9 .
Citation Information
Patent Citations
Synthesis method of edoxaban intermediate and intermediate product
CN106866452A
Multi-axis directional antenna system with stacked structure
KR102534807B1
Diamine derivatives
WO2003000680A1
Optically active diamine derivative and process for producing the same
WO2007032498A1
